Top 6 Momentum Stocks for September 27th

DENVER, Colo., Sept 27, 2023 (www.247marketnews.com)- The following stocks are the top performing U.S. stocks over the past week; Vaccitech (NASDAQ:VACC), Siyata Mobile (NASDAQ:SYTA), Soleno Therapeutics (NASDAQ:SLNO), Femasys (NASDAQ:FEMY), Immunovant (NASDAQ:IMVT), and Intercept Pharma (NASDAQ:ICPT)

Vaccitech and Siyata Mobile made yesterday’s list, while the other four were added after massive news driven moves.

Vaccitech (NASDAQ:VACC) opened trading last Wednesday at $1.68 and traded very lightly until Monday, when it opened at $1.64, a new 52-week low, but then, like someone flipped the switch, it took off to hit a high of $4.35, a new 52-week high. It may be rolling over as it closed yesterday at $2.82, down $0.34 (-10.76%), on 2.12M shares traded, but it’s still 59.43% higher for the 5-day period.

Its most recent announcement was “Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023” September 13, 2023.

We hoped that it would consolidate at $3, or better, but, so far, it’s not cooperating.

Siyata Mobile (NASDAQ:SYTA) opened trading last Wednesday at $2.05, after bouncing off its 52-week lows. It closed at $2.94, up $0.34 (+13.08%), on 115.4K shares traded. It’s 43.41% higher for the 5-day period.

Its most recent announcement was “Siyata Mobile Announces Follow-On Order from Large North American Waste Management Provider” September 18, 2023

It’s broken the downward trend on the one-month chart and is getting close to doing the same on the six-month chart. It still looks like it wants to challenge the $3.50 level.

Soleno Therapeutics (NASDAQ:SLNO) opened trading last Wednesday at $4.51 and traded very lightly until yesterday, when it opened at $21.00 and hit a new 52-week high of $30.30. It closed at $26.80, up $22.37 (+504.97%), on 41.8M shares traded. It’s 494.24% higher for the 5-day period.

Its most recent announcement was “Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome” September 26, 2023

Unless a bunch of shorters are still stuck in this, it’s hard to picture this running much higher until it’s had some time to consolidate in the twenties.

Femasys (NASDAQ:FEMY) opened trading last Wednesday at $0.33 and traded sideways until yesterday, when it opened at $1.22, hit a high of $1.66, before closing at $1.48, up $1.1484 (+346.32%), on 191.9M shares traded. It’s 359.66% higher for the 5-day period.

Its most recent announcement was “Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution” September 25, 2023

Immunovant (NASDAQ:IMVT) opened trading last Wednesday at $21.48 and traded sideways until yesterday, when it took off and hit a high of $41.7199 and closed at $39.96, up $19.68 (+97.04%), on 35.1M shares traded. It’s 86.03% higher for the 5-day period.

Its most recent announcements were “Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results” and “Immunovant Announces Proposed Offering of $300 Million of Common Stock” September 26, 2023

It’s now testing its 2020 trading levels.

Intercept Pharma (NASDAQ:ICPT) opened trading last Wednesday at $11.09 and traded sideway, until it took off yesterday and closed at $18.71, up $8.27 (+79.21%), on 37.3M shares traded. It’s 68.94% higher for the 5-day period.

Its most recent announcement was “Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases” September 26, 2023

Its price is probably not going to move much from here.

Link to disclosure here.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.